Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland

References

• Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–629. doi:10.1038/clpt.2011.18521900891
   PubMed Web of Science ®Google Scholar
• Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol. 2013;168(4):4234–4243. doi:10.1016/j.ijcard.2013.07.15123932037
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–2012. doi:10.1056/NEJMsa110305322111719
   PubMed Web of Science ®Google Scholar
• Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115. doi:10.1001/jama.2016.1620127893129
   PubMed Web of Science ®Google Scholar
• Lapatto-Reiniluoto O, Patinen L, Niemi M, Backman JT, Neuvonen PJ. Drug-related inadvertent deaths in a university hospital - a declining trend. Basic Clin Pharmacol Toxicol. 2015;117(6):421–426. doi:10.1111/bcpt.1243526111726
   PubMed Web of Science ®Google Scholar
• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41. doi:10.1016/j.tcm.2014.09.00125282448
   PubMed Web of Science ®Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397–404. doi:10.1002/cpt.66828198005
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784–792. doi:10.1182/blood-2008-04-14907018574025
   PubMed Web of Science ®Google Scholar
• Hindrics G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020. doi:10.1093/eurheartj/ehaa612
   Web of Science ®Google Scholar
• Vandell AG, Walker J, Brown KS, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017;103(22):1800–1805. doi:10.1136/heartjnl-2016-31090128689179
   PubMed Web of Science ®Google Scholar
• Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–2287. doi:10.1016/S0140-6736(14)61994-225769357
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–719. doi:10.1016/S0140-6736(98)04474-210073515
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–2303. doi:10.1056/NEJMoa131138624251363
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293. doi:10.1056/NEJMoa131066924251361
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. Novelli Ged. PLoS One. 2012;7(8):e44064. doi:10.1371/journal.pone.004406422952875
   PubMed Web of Science ®Google Scholar
• Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates. J Am Coll Cardiol. 2010;55(25):2804–2812. doi:10.1016/j.jacc.2010.03.00920381283
   PubMed Web of Science ®Google Scholar
• Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT Randomized clinical trial. JAMA. 2017;318(12):1115–1124. doi:10.1001/jama.2017.1146928973620
   PubMed Web of Science ®Google Scholar
• Carnes CA. What is the role of pharmacogenetics in optimization of warfarin dosing? Trends Cardiovasc Med. 2015;25(1):42–43. doi:10.1016/J.TCM.2014.10.00325476743
   PubMed Web of Science ®Google Scholar
• Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690. doi:10.1001/jama.287.13.169011926893
   PubMed Web of Science ®Google Scholar
• Ruff CT. Pharmacogenetics of Warfarin Therapy. Clin Chem. 2018;64(11):1558–1559. doi:10.1373/clinchem.2017.28492729941467
   PubMed Web of Science ®Google Scholar
• Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype-guided dosing versus conventional dosing of warfarin: a meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44(2):197–208. doi:10.1111/jcpt.1278230593674
   PubMed Web of Science ®Google Scholar
• Limdi N, McGwin G, Goldstein J, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in african-american and european-american patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312. doi:10.1038/SJ.CLPT.610029017653141
   PubMed Web of Science ®Google Scholar
• Swanson KM, Zhu Y, Rojas RL, et al. Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using the right drug, right dose, right time: using genomic data to individualize treatment (RIGHT) 10K warfarin cohort. PLoS One. 2020;15:5. doi:10.1371/JOURNAL.PONE.0233316
   Web of Science ®Google Scholar
• Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications. Lancet. 1999;354(9184):1124. doi:10.1016/S0140-6736(05)76918-X
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999–1008. doi:10.1056/NEJMoa070807818322281
   PubMed Web of Science ®Google Scholar
• Tomek A, Maťoška V, Kolářová T, et al. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology. 2013;125:3. doi:10.1159/000350407
   Web of Science ®Google Scholar
• FinnGen research project. https://www.finngen.fi/en. Accessed 919, 2020.
   Google Scholar
• Borodulin K, Vartiainen E, Peltonen M, et al. Forty-year trends in cardiovascular risk factors in Finland. Eur J Public Health. 2015;25(3):539–546. doi:10.1093/eurpub/cku17425422363
   PubMed Web of Science ®Google Scholar
• Aromaa A, Koskinen S. Health and Functional Capacity in Finland: Baseline Results of the Health 2000 Health Examination Survey. Helsinki: KTL, National Public Health Institute Finland; 2004. https://www.julkari.fi/handle/10024/78534.
   Google Scholar
• Rosendaal F, Cannegieter S, van der Meer F, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239. doi:10.1055/s-0038-16515878470047
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-0000619414839
   PubMed Web of Science ®Google Scholar
• Lehto M, Niiranen J, Korhonen P, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF registry. Pharmacoepidemiol Drug Saf. 2017;26(6):657–665. doi:10.1002/pds.419428317274
   PubMed Web of Science ®Google Scholar
• Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009;19(2):170–179. doi:10.1097/FPC.0b013e32831ebb3019151603
   PubMed Web of Science ®Google Scholar
• Finnish biobank Act (688/2012). http://www.finlex.fi/fi/laki/alkup/2012/20120688#Lid2180503. Accessed 919, 2020.
   Google Scholar
• Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63:e425–e431.29025819
   PubMed Web of Science ®Google Scholar
• Wadelius M, Sörlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2004;4(1):40–48. doi:10.1038/sj.tpj.650022014676821
   PubMed Web of Science ®Google Scholar
• Biss TT, Avery PJ, Williams MD, Brandão LR, Grainger JD. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost. 2013;11(2):373–375. doi:10.1111/jth.1207223279643
   PubMed Web of Science ®Google Scholar
• Baker WL, Johnson SG. Pharmacogenetics and oral antithrombotic drugs. Curr Opin Pharmacol. 2016;27:38–42. doi:10.1016/J.COPH.2016.01.00826878737
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7:8. doi:10.1371/journal.pone.0044064
   Web of Science ®Google Scholar
• Roth JA, Boudreau D, Fujii MM, et al. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther. 2014;95(6):636–643. doi:10.1038/clpt.2014.2624503627
   PubMed Web of Science ®Google Scholar
• Park YK, Lee MJ, Kim JH, et al. Genetic and non-genetic factors affecting the quality of anticoagulation control and vascular events in atrial fibrillation. J Stroke Cerebrovasc Dis. 2017;26(6):1383–1390. doi:10.1016/j.jstrokecerebrovasdis.2017.02.02228412319
   PubMed Web of Science ®Google Scholar
• Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94. doi:10.1111/j.1742-7843.2009.00494.x19961477
   PubMed Web of Science ®Google Scholar
• Rapola JM, Virtamo J, Korhonen P, et al. Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland. Eur J Epidemiol. 1997;13(2):133–138. doi:10.1023/A:10073804087299084994
   PubMed Web of Science ®Google Scholar
• Meckley LM. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost. 2008;100(2):229–239. doi:10.1160/TH07-09-055218690342
   PubMed Web of Science ®Google Scholar
• Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009;30(7):375–386. doi:10.1016/j.tips.2009.05.00119540002
   PubMed Web of Science ®Google Scholar